吡格列酮对空腹血糖受损合并高血压病患者血小板功能的影响

The effect of pioglitazone treatment on platelet function in patients with impaired fasting glucose and hypertension

空腹血糖受损(IFG)合并高血压病患者75例,随机分为吡格列酮降压组和常规降压组,两组均同时继续降压治疗,治疗组另加用盐酸吡格列酮15 mg/d,共12周,观察治疗前后血糖、血压、胰岛素抵抗指数(HOMA-IR)和血小板活化指标[二磷酸腺苷(ADP)诱导的血小板聚集率、血小板α-颗粒膜蛋白(GMP-140)、血小板激活复合物-1(PAC-1)表达率]的变化。结果显示,与治疗前比较,吡格列酮组治疗后空腹血糖、HOMA-IR、血小板活化各指标均明显降低,差异有统计学意义(P<0.01),血压、血脂与治疗前比较,差异无统计学意义;常规降压组血糖、血压、HOMA-IR、血小板活化指标治疗前后差异无统计学意义;与常规降压组比较,治疗后吡格列酮组血糖、HOMA-IR和血小板活化各指标明显降低,差异有统计学意义(P<0.01)。

75 patients with IFG and hypertension were divided into two groups： pioglitazone group and conventionaltreatment group, which simultaneously continued to take anti-hypertensive medication with pioglitazone （15 rag, once a day） added in pioglitazone group. At the beginning and the end of 12 weeks, fasting glucose, insulin, blood pressure, variables which can reflect the platelet activation were measured in the two groups. After 12 weeks＇ treatment, fasting glucose, HOMA-IR, indexes of platelet activation were significantly decreased in pioglitazone group when compared with pretreatment （ P 〈 0. 01 ） and conventional therapy group （ P 〈 0. 01 ）, but the blood pressure had no significant changes.